On 31 July 2018, orphan designation (EU/3/18/2047) was granted by the European Commission to Glycomine SARL, France, for liposomal mannose-1-phosphate for the treatment of phosphomannomutase 2-congenital disorder of glycosylation.
The sponsorship was transferred to Regintel Limited, Ireland, in May 2020.
|Disease / condition||
treatment of phosphomannomutase 2-congenital disorder of glycosylation
|Date of first decision||
|EU designation number||
Review of designation
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.